Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Shares Outstanding (Diluted Average) (2016 - 2023)

Historic Shares Outstanding (Diluted Average) for Ekso Bionics Holdings (EKSO) over the last 11 years, with Q1 2023 value amounting to $13.3 million.

  • Ekso Bionics Holdings' Shares Outstanding (Diluted Average) rose 446.26% to $13.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $13.3 million, marking a year-over-year increase of 446.26%. This contributed to the annual value of $13.0 million for FY2022, which is 564.84% up from last year.
  • According to the latest figures from Q1 2023, Ekso Bionics Holdings' Shares Outstanding (Diluted Average) is $13.3 million, which was up 446.26% from $13.0 million recorded in Q4 2022.
  • In the past 5 years, Ekso Bionics Holdings' Shares Outstanding (Diluted Average) ranged from a high of $13.3 million in Q1 2023 and a low of $5.0 million during Q3 2019
  • For the 5-year period, Ekso Bionics Holdings' Shares Outstanding (Diluted Average) averaged around $10.8 million, with its median value being $12.7 million (2021).
  • As far as peak fluctuations go, Ekso Bionics Holdings' Shares Outstanding (Diluted Average) crashed by 9185.9% in 2019, and later surged by 10343.4% in 2021.
  • Ekso Bionics Holdings' Shares Outstanding (Diluted Average) (Quarter) stood at $5.0 million in 2019, then surged by 43.37% to $7.2 million in 2020, then surged by 71.26% to $12.3 million in 2021, then rose by 5.65% to $13.0 million in 2022, then rose by 2.58% to $13.3 million in 2023.
  • Its last three reported values are $13.3 million in Q1 2023, $13.0 million for Q4 2022, and $13.1 million during Q3 2022.